iLoF is a technology company.
iLoF has raised $4.0M across 1 funding round.
iLoF has raised $4.0M in total across 1 funding round.
iLoF has raised $4.0M in total across 1 funding round.
iLoF's investors include 01 Advisors, Accel, Amplo, Axiom Partners, Behold Ventures, Jenny Fielding, Scott Hartley, Faber, H.I.G. Capital, IA Ventures, Incisive Ventures, Lightspeed Venture Partners.
iLoF (Intelligent Lab on Fiber) is a digital health startup developing an AI-powered photonics platform that accelerates personalized drug discovery and development by detecting label-free nanosized biomarkers in blood samples to create digital libraries of biological profiles and disease signatures.[1][2][5] The platform serves pharmaceutical companies, biotechs, clinical researchers, and hospitals, solving key challenges in clinical trials such as patient stratification, screening heterogeneity, and high costs—particularly for complex diseases like Alzheimer’s, ovarian cancer, and COVID-19—by enabling rapid (<10 seconds), non-invasive, low-cost analysis that cuts screening time by 70% and costs by 40%.[3][4][6][7] With over €14M ($5M+ recently) in funding, a team of 31, revenue from paid pilots, and partnerships across 15 countries including UCL, Oxford, and global pharmas, iLoF demonstrates strong growth momentum through expanding its biomarker library (over 1,000 profiles) and U.S. market entry via Luminate NY.[2][3][4][6]
Founded in 2019 as a British startup with Portuguese roots, iLoF was co-founded by CEO Luís Valente, a serial entrepreneur from the UK/Portugal, and COO Mehak Mumtaz, an Oxford graduate and personalized medicine expert, who assembled a team of physicists, biologists, data scientists, and over 20 scientists/inventors.[2][4][6] The idea emerged from researching over 100 hospitals, biotechs, and pharmas across 15 countries, identifying barriers in drug discovery like inefficient patient screening for heterogeneous diseases such as Alzheimer’s; this led to their photonics-based platform using focused laser spectrums on blood samples.[4] Early traction included partnerships with UCL, Maastricht University, Oxford, and Danish National Biobank for data collection, revenue-generating pilots with biotechs and pharmas on four continents, and awards like CB Insights Top 150 and Financial Times Top 7 Transformational Business.[3][4]
iLoF rides the wave of precision medicine and AI-driven drug discovery, where market forces like rising clinical trial failure rates (due to patient heterogeneity) and demand for personalized treatments in neurodegenerative diseases (e.g., Alzheimer’s affecting millions) create tailwinds—pharma R&D spending exceeds $200B annually, yet 90% of trials fail, making tools like iLoF's stratification critical.[3][4][7] Timing aligns with photonics/optics advancements and post-COVID emphasis on rapid diagnostics, amplified by U.S. expansion into Rochester's OPI hub via Luminate NY.[4] iLoF influences the ecosystem by partnering with top institutions/pharmas, improving trial success, and enabling data-driven therapies, potentially reshaping healthcare for complex diseases globally.[1][6]
iLoF is poised to scale its biomarker library and platform agnosticism beyond Alzheimer’s to oncology and infectious diseases, leveraging €14M funding for U.S./global growth, larger pilots, and team expansion.[6][7] Trends like multimodal AI data integration and regulatory pushes for patient-centric trials will propel it, potentially evolving into a standard tool for pharma R&D efficiency. As personalized medicine matures, iLoF's photonics edge could redefine drug development speed and success, delivering on its promise to get life-saving treatments to patients faster.[1][2]
iLoF has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $4.0M Seed | 01 Advisors, Accel, Amplo, Axiom Partners, Behold Ventures, Jenny Fielding, Scott Hartley, Faber, H.I.G. Capital, IA Ventures, Incisive Ventures, Lightspeed Venture Partners, M12, Norwest Venture Partners, One Way Ventures, Owl Rock Capital Partners, Pitbull Ventures, Quiet Capital, SNR, Thirty Five Ventures, Adam D'Angelo, Armando Mann, Charlie Cheever, David Petraeus, James Gwertzman, Stefan Lindeberg |